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Abstract
Background  and  objectives:  Isoﬂurane  is  halogenated  volatile  ether  used  for  inhalational
anesthesia.  It  is  widely  used  in  clinics  as  an  inhalational  anesthetic.  Neonatal  hypoxic  ischemia
injury ensues  in  the  immature  brain  that  results  in  delayed  cell  death  via  excitotoxicity  and
oxidative stress.  Isoﬂurane  has  shown  neuroprotective  properties  that  make  a  beneﬁcial  basis
of using  isoﬂurane  in  both  cell  culture  and  animal  models,  including  various  models  of  brain
injury. We  aimed  to  determine  the  neuroprotective  effect  of  isoﬂurane  on  hypoxic  brain  injury
and elucidated  the  underlying  mechanism.
Methods:  A  hippocampal  slice,  in  artiﬁcial  cerebrospinal  ﬂuid  with  glucose  and  oxygen
deprivation,  was  used  as  an  in  vitro  model  for  brain  hypoxia.  The  orthodromic  population
spike and  hypoxic  injury  potential  were  recorded  in  the  CA1  and  CA3  regions.  Amino  acid
neurotransmitters  concentration  in  perfusion  solution  of  hippocampal  slices  was  measured.
Results: Isoﬂurane  treatment  caused  delayed  elimination  of  population  spike  and  improved
the recovery  of  population  spike;  decreased  frequency  of  hypoxic  injury  potential,  post-
poned the  onset  of  hypoxic  injury  potential  and  increased  the  duration  of  hypoxic  injury
potential. Isoﬂurane  treatment  also  decreased  the  hypoxia-induced  release  of  amino  acid
neurotransmitters  such  as  aspartate,  glutamate  and  glycine  induced  by  hypoxia,  but  the  levels
of -aminobutyric  acid  were  elevated.  Morphological  studies  showed  that  isoﬂurane  treatment
attenuated  edema  of  pyramid  neurons  in  the  CA1  region.  It  also  reduced  apoptosis  as  evident
by lowered  expression  of  caspase-3  and  PARP  genes.
Conclusions:  Isoﬂurane  showed  a  neuro-protective  effect  on  hippocampal  neuron  injury  induced
by hypoxia  through  suppression  of  apoptosis.
© 2016  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).∗ Corresponding author.
E-mail: zhaodean17@gmail.com (D-A. Zhao).
http://dx.doi.org/10.1016/j.bjane.2015.04.008
0104-0014/© 2016 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Isoﬂurano  fornece  neuroprotec¸ão em  lesão  cerebral  hipóxico-isquêmica  neonatal
por  inibic¸ão da  apoptose
Resumo
Justiﬁcativa  e  objetivos:  Isoﬂurano  é  um  éter  volátil  halogenado  usado  para  anestesia  por
via inalatória.  É  amplamente  utilizado  na  clínica  como  um  anestésico  para  inalac¸ão.  A  lesão
hipóxico-isquêmica  neonatal  ocorre  no  cérebro  imaturo  e  resulta  em  morte  celular  tardia  via
excitotoxicidade  e  estresse  oxidativo.  Isoﬂurano  mostrou  possuir  propriedades  neuroprotetoras
que formam  uma  base  benéﬁca  para  o  seu  uso  tanto  em  cultura  de  células  quanto  em  modelos
animais,  incluindo  vários  modelos  de  lesão  cerebral.  Nosso  objetivo  foi  determinar  o  efeito
neuroprotetor  de  isoﬂurano  em  hipóxia  cerebral  e  elucidar  o  mecanismo  subjacente.
Métodos: Fatias  de  hipocampo,  em  ﬂuido  cerebrospinal  artiﬁcial  (CSFA)  com  glicose  e  privac¸ão
de oxigênio,  foram  usadas  como  um  modelo  in  vitro  de  hipóxia  cerebral.  O  pico  de  populac¸ão
ortodrômica  (PPO)  e  o  potencial  de  lesão  hipóxica  (PLH)  foram  registrados  nas  regiões  CA1  e
CA3. A  concentrac¸ão  de  neurotransmissores  de  aminoácidos  na  soluc¸ão  de  perfusão  das  fatias
de hipocampo  foi  medida.
Resultados:  O  tratamento  com  isoﬂurano  retardou  a  eliminac¸ão  do  PPO  e  melhorou  a
recuperac¸ão do  PPO;  diminuiu  a  frequência  do  PLH,  retardou  o  início  do  PLH  e  aumentou  a
durac¸ão do  PLH.  O  tratamento  com  isoﬂurano  também  diminuiu  a  liberac¸ão  de  neurotrans-
missores de  aminoácidos  induzida  pela  hipóxia,  como  aspartato,  glutamato  e  glicina,  mas  os
níveis de  ácido  -aminobutírico  (GABA)  estavam  elevados.  Estudos  morfológicos  mostram  que  o
tratamento  de  edema  com  isoﬂurano  atenuou  o  edema  de  neurônios  piramidais  na  região  CA1.
Também  reduziu  a  apoptose,  como  mostrado  pela  expressão  reduzida  da  caspase-3  e  genes
PARP.
Conclusões:  Isoﬂurano  mostrou  um  efeito  neuroprotetor  na  lesão  neuronal  no  hipocampo
induzida por  hipóxia  através  da  supressão  de  apoptose.
© 2016  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um
artigo Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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ypoxic  brain  injuries  cause  several  pathologic  conditions,
hich  may  also  occur  during  neuro-  and  cardiac-surgeries
nd  anesthesia.  The  mechanism  underlying  such  hypoxic
rain  injury  is  still  unclear.  How  to  protect  the  brain  from
ypoxic  injury  and  how  to  treat  hypoxic  brain  injury  remains
linically  challenging.  Hypothermia  and  pre-ischemia  treat-
ents  have  been  shown  protective  effect  on  the  brain1,2
et  difﬁcult  to  implement  clinically,  while  pharmacological
reatment  clinically  more  practical.  During  the  recent  three
ecades,  the  neuroprotective  effect  of  anesthetic  drugs  has
rawn  high  attention  from  clinicians.
Isoﬂurane  [2-chloro-2-[diﬂuoromethoxy)-1;  1.1-triﬂuoro-
thane,  CHF2-O-CHCl-CF3]  is  a  halogenated  ether  used
or  inhalational  anesthesia.  Together  with  enﬂurane  and
alothane,  it  replaced  the  ﬂammable  ethers  used  in  the
ioneer  days  of  surgery.  Its  name  comes  from  being  a
tructural  isomer  of  enﬂurane,  hence  they  have  the  same
mpirical  formula.  It  is  a  racemic  mixture  of  (R)  and  (S)
ptical  isomers.  Its  use  in  human  medicine  is  now  start-
ng  to  decline,  being  replaced  with  sevoﬂurane,  desﬂurane,
nd  the  intravenous  anesthetic  propofol.  Isoﬂurane  is  still
requently  used  for  veterinary  anesthesia.  Propofol  could
educe  arterial  blood  ﬂow  in  brain,  intracranial  pressure,
nd  metabolism  maintaining  blood  supply  and  oxygen  ratio.
t  improved  the  oxygen  supply  during  hypoxia  suggesting
e
h
trotective  effects  of  propofol  against  hypoxic  brain
amage.3--5 Studies  suggest  that  propofol  plays  a  role
n  central  nervous  system  (CNS)  protection  through  the
odulation  of  Ca2+,  oxygen  free  radicals,  -aminobutyric
cid  (GABA)  receptor  and  N-methyl-d-aspartate  (NMDA)
eceptor.6--9 Yet  some  data  suggest  that  propofol  had  no
rain  protective  effect  after  cardiac  surgery  and  even
orsened  brain  hypoxia10 and  that  hypothermia  is  neuro-
rotective  rather  than  propofol.1 The  volatile  anesthetics
ll  differ  in  potency,  adverse  effects,  and  cost,  and  are
sed  extensively  during  surgery  in  human  neonates  and
uring  neonatal  animal  research.  Isoﬂurane  was  reviewed
o  have  neuroprotective  functions  in  studies  with  neonatal
ypoxic  ischemic  brain  injury.11 Isoﬂurane  has  been  studied
n  animal  models  of  various  diseases,  such  as  lipopolysac-
haride  (LPS)-induced  acute  inﬂammation  of  the  lung,12
cute  lung  injury,13 glucose-induced  oxidative  stress,14 renal
schemia/reperfusion  injury,15 and  cardiac  injury.16 Isoﬂu-
ane  was  shown  to  provide  protection  from  injury  and
mprove  various  negative  functional  outcomes  in  these
odels.
Neonatal  hypoxia  ischemia  is  a  major  cause  of  mortal-
ty  and  neurological  deﬁcits  such  as  cerebral  palsy,  mental
etardation,  and  epilepsy  in  the  perinatal  period.17 Sev-
ral  pathophysiological  factors  have  been  implicated  in  the
ypoxia  ischemia,  including  inﬂammatory  mediators,  exci-
otoxicity,  and  oxidative  stress.18 The  use  of  isoﬂurane  as
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oIsoﬂurane  provides  neuroprotection  in  neonatal  hypoxic  isch
an  anesthetic  in  the  surgery  for  modeling  neonatal  hypoxia
ischemia  has  led  to  speculations  that  isoﬂurane  may  be  hav-
ing  protective  effects  on  neonates.  In  particular,  isoﬂurane
shows  neuroprotection  in  several  stroke  models  including
subarachnoid  hemorrhage  (SAH),19 middle  cerebral  artery
occlusion  (MCAO),20,21 intracerebral  hemorrhage,22 trau-
matic  brain  injury,23 and  neonatal  hypoxic  ischemic  brain
injury.24 A  study  showed  that  2  h  exposure  to  isoﬂurane  did
not  cause  neuroapoptosis  in  adult  brains  and  suggests  that
delayed  reduction  in  astroglial  processes  after  isoﬂurane
exposure  may  explain  why  some  volatile  anesthetics  can
confer  neuroprotection  after  experimental  stroke.25
Isoﬂurane  has  been  claimed  to  be  both  neuroprotective
and  neurotoxic  yet  the  claim  about  isoﬂurane  causing  neural
apoptosis  remains  controversial.  In  this  study,  we  investi-
gated  the  effects  of  isoﬂurane  exposures  on  hippocampus
slices  of  rat  brain  and  assessed  the  apoptotic  function.  To
investigate  the  effects  and  mechanisms  of  isoﬂurane,  neu-
rological  changes,  degrees  of  neurogenesis,  and  apoptosis
were  studied  in  rats  after  exposure  to  various  concentra-
tions  of  isoﬂurane.  The  overall  goal  of  this  study  is  to  ﬁnd
evidences  demonstrating  that  isoﬂurane  treatment  has  neu-
roprotective  effects  on  brain  during  hypoxia.  Similar  to  the
results  in  several  studies,  we  found  no  evidence  of  brain  cell
death  or  neurogenesis  in  neonatal  hypoxic  ischemic  brain
tissues  after  isoﬂurane  anesthesia.
Methods
Experimental  animals
All  the  animal  protocols  were  approved  by  the  Institutional
Animal  Ethical  Committee.  Animals  were  housed  and  main-
tained  under  deﬁned  protocol  with  a  12  h  light--dark  cycle
and  the  room  temperature  was  maintained  at  25  ±  1 ◦C.  Sixty
Sprague  Dawley  (SD)  rats  at  postnatal  day  (P)  7  (weight,
16--18  g)  were  randomly  divided  into  ﬁve  groups  (n  =  12).
Group  (i)  control  reviewed  normoxia  treatment.  Forty  eight
SD  rats  were  subjected  to  hypoxia  then  distributed  in  fur-
ther  four  groups:  (ii)  hypoxia  (Hx);  (iii)  Hx-isoﬂurane  0.5%
treated;  (iv)  Hx-isoﬂurane  1.5%  treated;  (v)  Hx-isoﬂurane
2.5%  treated.
Neonatal  hypoxia--ischemia
Rats  of  groups  (ii--v)  were  anesthetized  using  3%  halothane
followed  by  a  3  mm  midline  cervical  incision  as  per  standard
procedure.  The  left  carotid  artery  was  exposed  and  coagu-
lated  using  a  bipolar  electrocautery  unit  followed  by  closure
of  the  incision  using  topical  surgical  adhesive.  After  a  3  h
recovery  period,  the  mice  were  then  placed  in  a  chamber
containing  8%  O2/92%  N2 for  45  min.  The  temperature  in  the
chamber  was  maintained  at  37 ◦C.  Control  mice  (zero  time)
were  anesthetized  and  underwent  exploration  of  left  carotid
artery  without  cauterization.Isoﬂurane  exposure
Rats  were  prepared  for  isoﬂurane  exposure  18  h  after
hypoxia.  Rats  were  placed  in  plastic  containers  and  exposed
O
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o  isoﬂurane  for  6  h  continuously  using  air  as  a  carrier  with
 total  gas  ﬂow  of  2  L/min.  During  the  isoﬂurane  expo-
ure,  containers  were  maintained  to  37 ◦C  using  a  heating
evice.  The  levels  of  isoﬂurane,  oxygen  and  carbon  diox-
de  were  monitored  in  the  chamber  using  a  gas  monitor.
fter  6  h,  isoﬂurane  administration  was  terminated  and  the
ats  were  exposed  to  air  solely.  After  observing  free  move-
ent  in  rats,  they  were  placed  back  into  the  maternal  cage.
he  respiratory  frequency  and  skin  color  of  the  rats  were
onitored  during  isoﬂurane  exposure.  Rats  were  observed
or  any  case  of  apnea  or  hypoxia  and  were  immediately
xposed  to  air  and  excluded  from  the  experiment.  Rats  in
he  control  group  were  placed  into  similar  container  as  the
ats  in  the  isoﬂurane  group,  but  were  exposed  to  air  alone
or  6  h.
issue  preparation
ats  were  anesthetized  with  isoﬂurane  after  the  recov-
ry  period.  A  transcardial  perfusion  was  performed  with
uffered  10%  formalin  phosphate  according  to  previous  pro-
ocol.  The  brains  were  extracted  from  the  skulls  through
urgical  procedure.  Brains  were  stored  in  buffered  10%
ormalin  for  48  h.  Then  the  tissue  was  frozen-sectioned
nto  30  mm  slices  using  a  Leica  SM2000R  microtome  (Leica,
ermany).  Sections  from  the  hippocampal  region  were  ran-
omly  selected  for  histological  and  other  studies.
istopathological  examination
he  rats  exposed  to  isoﬂurane  as  well  as  control  group
ere  sacriﬁced  at  6  h (n  =  3).  Hippocampal  slices  from  each
roup  were  ﬁxed  in  0.1%  methanol  and  embedded  in  wax
fter  dehydration.  Tissue  blocks  were  sliced  in  5  mm  thick
ections  and  stained  with  hematoxylin  and  eosin  (H&E)  as
er  standard  protocol.  The  results  were  examined  in  detail
nder  a  light  microscope  so  as  to  determine  morphological
hanges  in  parts  of  the  CA1  and  CA3  regions.
xtracellular  potential  recording
lectric  probes  were  inserted  into  Schaffer  lateral  ﬁber  at
A3  and  extracellular  potential  was  recorded  as  described
arlier.  Stimuli  (0.6  mA,  0.1  Hz,  100  ms)  were  given  with
 10-s  interval.  Evoked  potentials  including  orthodromic
opulation  spike  (OPS)  and  hypoxia  injury  potential  (HIP)
ere  recorded  at  CA1.  Only  brain  slices  that  had  stable  OPS
43  mV)  for  at  least  20  min  were  selected  for  experiments.
ypoxic  groups  were  incubated  in  ASCF  without  glucose
nd  oxygen  (ASCFOGD)  for  15  min  followed  by  normal  ASCF
erfusion.  In  hypoxic  and  treatment  groups,  every  OPS  was
ecorded  before  its  disappearance.  Each  group  contained
ight  samples.  OPS  decay  is  deﬁned  as  the  time  period
hen  OPS  become  undetectable  after  oxygen  deprivation.
he  amplitude  of  OPS  recovery  is  deﬁned  as  the  ratio
f  OPS  amplitude  after  1  h  of  normal  ASCF  perfusion  over
PS  amplitude  before  oxygen  deprivation.  The  ratio  of
PS  recovery  is  deﬁned  as  the  percentage  of  hippocampal
lices  in  which  OPS  amplitude  recovery  reach  60%  of  OPS
mplitude  before  oxygen  deprivation.  HIP  onset  is  deﬁned
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s  the  time  period  when  HIP  is  recorded  after  oxygen
eprivation.  HIP  duration  is  deﬁned  as  how  long  HIP  lasts.
IP  incidence  is  deﬁned  as  the  percentage  of  hippocampal
lices  in  which  HIP  were  recorded  after  oxygen  deprivation.
igh  performance  liquid  chromatographic  (HPLC)
nalysis
at  brain  hippocampal  slices  from  each  group  (n  =  3)  were
ncubated  in  ASCF  (NaCl  124  Mm;  KCl  3.3  mM;  NaH2PO4
.24  mM;  MgSO4 2.4  mM;  NaHCO3 25.7  mM;  CaCl2 2.4  mM)
ith  and  without  glucose  (10.0  mM)  at  37.5 ◦C  for  2--2.30  h.
he  ﬂowing  volume  was  200  mL  min/L.  The  ASCF  from  15  min
f  perfusion  from  each  group  was  collected  and  centrifuged
o  clear  supernatant.  Supernatant  was  processed  for  HPLC
nalysis  as  per  standard  protocol  with  necessary  modiﬁca-
ions.  The  mobile  phase  A  was  Sodium  Acetate  (0.5  M,  pH
.0)  with  0.05%  THF.  The  mobile  phase  B  was  methanol.  The
ollowing  washing  gradients  (minutes,  Phase  B%)  were  used:
,  30%;  7,  60%;  and  9,  30%;  with  velocity  of  0.9  mL/min,
emperature  at  35 ◦C,  lem  at  330  nm  and  lex  at  456  nm.
erivation  agent  used  was  OPA,  2-MCE,  Boric  acid--sodium
ydroxide  and  methanol  (Ph  9.6).  Derivation  agent  (25  mL)
nd  sample  (25  mL)  was  incubated  for  2  min  at  room  tem-
erature.  Injection  volume  was  20  mL.  Standard  curves  were
repared  using  10;  5;  2.5;  1.25  and  0.625  mM  of  Asp,  Glu,
ln,  Gly  or  GABA  (HPLC  grade).  The  concentrations  (mM)  of
sp,  Glu,  Gln,  Gly  and  GABA  in  perfusion  ASCF  were  calcu-
ated  based  on  standard  curves.
eal  time-PCR  (RT-PCR)
ippocampal  slices  from  each  group  (n  =  3)  were  snap  frozen
t  −80 ◦C  in  RNAsefree  microfuge  tubes  at  the  moment  of
issection  for  RT-PCR.  Total  RNA  was  isolated  from  tissues
sing  Trizol  reagent  (Invitrogen,  USA)  according  to  manu-
acturer’s  instructions.  Total  RNA  (1  g)  was  incubated  with
00  ng  random  hexamers,  0.5  mM  dNTPs,  and  RNase-free
ater  at  65 ◦C  for  10  min  (all  from  Invitrogen).  Then,  5×  ﬁrst
trand  buffer,  5  mM  DTT,  40  U  RNAse  A,  and  200  U  reverse
ranscriptase  (SuperScript  III)  was  added.  The  reaction  mix-
ure  was  incubated  at  room  temperature  for  5  min  followed
y  at  50 ◦C  for  60  min,  at  70 ◦C  for  15  min,  and  at  4 ◦C  for
0  min.  Real-time  quantitative  PCR  was  performed  using  an
BI  7500  Real  Time  PCR  System  (Applied  Biosystems).  Assays
or  target  cDNA  levels  were  performed  using  TaqMan  MGB
robes  labeled  with  FAM  dye  (Applied  Biosystems)  in  a  20  L
eaction  containing  2  L  of  cDNA,  ROX  passive  reference
yes  and  TaqMan  Universal  PCR  mix  (Applied  Biosystems).
he  speciﬁc  primer  sets  used  and  their  part  number  are:
arp1  poly  (ADP-ribose)  polymerase  1  25591  Rn00565018  mL
nd  Casp3  caspase  3,  apoptosis  related  cysteine  protease
5402  Rn00563902  mL.  Relative  quantities  of  both  mRNAs
ere  established  by  normalizing  their  levels  to  that  of  18S
n  the  same  cDNA.tatistical  analysis
ll  values  are  expressed  as  mean  with  standard  devi-
tions  (SD).  Data  were  analyzed  using  the  SPSS  v.17
e
o
G
eD-A.  Zhao  et  al.
nd  Systat  SigmaPlot  10.0  statistical  software.  Statis-
ical  signiﬁcance  was  calculated  by  Student’s  t  test
nd  one  way  analysis  of  variance  (ANOVA)  for  multiple
omparisons.  p-Values  <  0.05  were  considered  statistically
igniﬁcant.
esults
ffect  of  isoﬂurane  treatment  on  OPS  and  HIP  after
eonatal--ischemia  hypoxia
PS  and  HIP  were  recorded  at  the  CA1  region.  In  the  hypoxia
roup,  the  average  decay  time  of  OPS  was  144  ±  21  s;  the
atio  of  OPS  recovery  was  22%  and  the  amplitude  of  recov-
ry  was  24  ±  9%.  In  1.5  and  2.5%  isoﬂurane  exposure  groups,
he  decay  time  of  OPS  was  signiﬁcantly  prolonged  and
he  ratio  of  OPS  recovery  and  the  amplitude  of  recovery
ere  increased  as  compared  with  that  of  hypoxia  group.
o  signiﬁcant  changes  of  the  decay  time,  recovery  ratio
nd  amplitude  of  OPS  were  found  in  0.5%  isoﬂurane  expo-
ure  group  (Fig.  1A).  In  the  hypoxic  group,  the  average
nset  time  of  HIP  was  403  ±  56  s;  the  average  duration  of
IP  was  104  ±  14  s  and  the  incidence  of  HIP  is  approximate
00%.  The  incidence  of  HIP  was  reduced;  the  onset  of  HIP
as  postponed  and  the  duration  of  HIP  was  extended  in
.5  and  2.5%  isoﬂurane  exposure  groups  as  compared  with
hat  of  hypoxic  group.  The  above  parameters  were  sta-
istically  not  signiﬁcant  in  0.5%  isoﬂurane  exposure  group
Fig.  1B).
ffect  of  isoﬂurane  exposure  on  release  of  amino
cid neurotransmitters
mino  acid  neurotransmitters  like  such  as  aspartate  (Asp),
lutamate  (Glu),  glutamine  (Gln),  glycine  (Gly)  and  GABA
re  commonly  circulated  and  have  important  functions  in
NS.  The  high  concentration  of  excitatory  amino  acids  (EAA)
n  synaptic  cleft  and  extracellular  ﬂuid  during  hypoxia  is  a
ommon  pathway  causing  excitatory  toxicity  and  neuronal
eaths.  Most  amino  acid  neurotransmitter  assays  measure
he  total  amount  of  amino  acids  in  speciﬁc  brain  areas  or
uclei,  which  may  also  contain  amino  acids  from  protein
etabolism.  Thus,  the  total  amino  acid  amount  of  the  hip-
ocampus  may  not  reﬂect  the  amount  of  amino  acids  as
 neurotransmitter.  In  this  study,  we  directly  measure  the
oncentration  of  amino  acid  neurotransmitters  in  perfusion
olution  of  hippocampal  slices  during  hypoxia  using  HPLC.
he  concentrations  of  neurotransmitters  Asp,  Glu,  Gly  and
ABA  were  signiﬁcantly  (p  <  0.05)  increased  in  the  hypoxic
roup  as  compared  with  that  of  normoxia  control  group
Table  1).  The  concentrations  of  Asp,  Glu,  Gly  and  GABA
ere  increased  by  1.32;  1.27;  1.78;  1.17  folds,  respectively.
soﬂurane  exposure  reduced  the  levels  of  Asp,  Glu  and  Gly  in
ose-dependent  manner  especially  at  1.5%  and  2.5%.  How-
ver,  isoﬂurane  exposure  continuously  increased  the  levels
f  GABA  release  with  statistical  signiﬁcance.  The  level  of
ln  release  was  altered  neither  by  hypoxia  nor  by  isoﬂurane
xposure  (Table  1).
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oFigure  1  The  effect  of  isoﬂurane  on  OPS  and  HIP.  Decay  time  
(s), duration  (s)  and  incidence  (%)  for  HIP  (B)  were  estimated  a
Isoﬂurane  improves  morphological  changes  in
hypoxic hippocampal  slice
The  histological  studies  sing  HE  staining  (Fig.  2)  showed
that  pyramid  neurons  in  the  CA1  region  of  the  hippocampus
became  swollen.  The  boundaries  of  cells  become  blurred
and  the  nuclei  were  dark  and  shrunken.  HE  data  suggests
that  cell  damage  occurred  in  the  hypoxic  group.  Further-
more,  isoﬂurane  treatment  ameliorated  those  morphologic
changes  of  pyramid  neurons  induced  by  hypoxia  in  dose-
dependent  manner.
w
t
a
w
Table  1  The  effect  of  isoﬂurane  on  release  of  amino  acids  neuro
Group  Asp  Glu  
Control  2.03  ±  0.12  1.85  ±  0.12  
Hypoxia (Hx)  2.68  ±  0.14a 2.35  ±  0.09a
Hx-ISF  0.5%  2.61  ±  0.15a 2.42  ±  0.11a
Hx-ISF  1.5%  2.44  ±  0.13a,b 2.01  ±  0.14a,b
Hx-ISF  2.5%  2.41  ±  0.14a,b 1.92  ±  0.12b
ISF, isoﬂurane.
a p < 0.05 vs. the normoxia control group.
b p < 0.05 vs. the hypoxic group.ecovery  rate  (%)  and  amplitude  recovery  (%)  for  OPS  (A);  onset
aterials  and  Methods  (n  =  3;  *  p  <  0.05  vs.  hypoxic  group).
soﬂurane  suppressed  neonatal  hypoxia  ischemia
nduced apoptosis
e  quantitated  levels  of  caspase-3  and  PARP  mRNA  from
he  hippocampus  using  RT-PCR.  Relative  quantities  of  both
RNAs  were  established  by  normalizing  their  levels  to  that
f  18S  in  the  same  cDNA.  The  log  expression  levels  of  genes
ere  expressed  in  terms  of  fold-change  compared  to  con-
rol  animals.  Fig.  3  shows  that  caspase-3  mRNA  was  elevated
bout  2-fold  after  neonatal  hypoxia  ischemia  as  compared
ith  normoxia  control.  Increases  in  caspase-3  mRNA  is  a
transmitters  from  hippocampal  slices  (pmoL/L).
Gln  Gly  GABA
0.77  ±  0.05  1.05  ±  0.07  1.79  ±  0.08
0.76  ±  0.05  1.87  ±  0.04a 2.09  ±  0.06a
0.75  ±  0.04  1.78  ±  0.07a 2.21  ±  0.09a,b
0.71  ±  0.05  1.65  ±  0.09a 2.43  ±  0.12a,b
0.72  ±  0.04  1.57  ±  0.07a,b 2.55  ±  0.14a,b
618  D-A.  Zhao  et  al.
Figure  2  HE  staining  of  hippocampal  slices.  (A)  normoxia  control;  (B)  hypoxia  (Hx);  (C)  Hx-isoﬂurane  0.5%;  (D)  Hx-isoﬂurane  1.5%;
(  in  M
d
A
c
t
t
t
i
d
r
w
p
b
D
T
i
n
b
i
r
O
t
h
p
p
t
B
o
w
s
hE) Hx-isoﬂurane  2.5%.  HE  staining  was  performed  as  described
irect  evidence  of  apoptosis  induction  in  hippocampal  slices.
poptosis  induction  requires  activation  of  caspase-3,  which
leaves  nuclear  substrate  PARP.  Analysis  of  PARP  mRNA  shows
hat  its  level  increased  1.86-fold  after  hypoxia  as  compared
o  normoxia  control.  Increases  in  PARP  mRNA  conﬁrmed
he  apoptosis  induction  in  hippocampal  slices.  Furthermore,
soﬂurane  exposure  to  these  tissues  showed  dose-dependent
ecrease  in  the  expression  levels  of  both  genes.  Isoﬂu-
ane  decreased  the  levels  of  caspase-3  and  PARP  mRNAs
ith  statistical  signiﬁcance.  These  results  show  that  apo-
tosis  induced  by  neonatal  hypoxia  ischemia  is  suppressed
y  isoﬂurane  exposure.
iscussionhis  study  investigated  the  effects  of  the  volatile  anesthetic
soﬂurane  on  possible  mechanisms  of  anesthetic-induced
europrotection  and  neurotoxicity  in  hippocampus  of  rat
a
a
r
gaterial  and  Methods  (n  =  3).
rain  under  hypoxia  ischemia.  We  mainly  observed  that
soﬂurane  does  not  alter  neurogenesis,  nor  does  it  cause  neu-
onal  cell  death,  in  various  formations  of  the  hippocampus.
ur  ﬁndings  demonstrate  that  isoﬂurane  causes  neuropro-
ection  by  suppressing  apoptosis  induced  by  hypoxia.
The  hippocampal  slice  has  been  commonly  used  in
ypoxia-induced  brain  injury  related  research  and  for  their
harmacologic  protection.  The  pyramid  neurons  in  the  hip-
ocampus  are  the  most  sensitive  cells  to  hypoxia,  of  which,
he  pyramid  neurons  in  CA1  are  more  vulnerable  to  hypoxia.
ecause  synapses  is  formed  between  CA1  and  CA3,  the
rthodromic  population  spike  (OPS)  can  be  recorded  in  CA1
hen  Schaffer  collateral  in  CA3.  Thus  the  OPS  demon-
trate  apparent  changes  during  hypoxia.  Previous  studies
ave  shown  a  reduction  of  OPS  amplitude  during  hypoxia,
n  indicator  of  synaptic  dysfunction  and  loss  of  excitatory
bility.  Such  OPS  changes  are  reversible  if  oxygen  supply  is
estored  in  time  and  the  delay  of  OPS  disappearance  sug-
ests  that  the  neurons  are  less  vulnerable  to  hypoxia.26 Thus,
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Figure  3  Quantitative  real  time-PCR  for  caspase-3  (A)  and
PARP (B).  Total  RNA  were  isolated  from  hippocampul  slices
(n =  3).  The  cDNA  was  synthesized  and  qRT-PCR  was  performed
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neurons  and  protects  the  synaptic  functions  from  hypoxic
damage.  Isoﬂurane  reduces  the  levels  of  hypoxia-inducedas described  in  Materials  and  Methods.
the  decay  time  of  OPS  after  hypoxia  can  be  used  as  a  param-
eter  to  evaluate  tolerance  of  neurons.  The  hypoxic  injury
potential  (HIP)  is  an  indicator  of  the  irreversible  hypoxic
damage  induced  in  hippocampal  slices.27,28 The  onset  and
duration  of  HIP  is  correlated  with  hypoxic  damage.  The
longer  HIP  appearance  correlates  with  easier  recovery  for
hippocampal  slice  after  restoration  of  oxygen  supply.  If  onset
of  HIP  is  postponed  or  extended,  neuron  damage  will  be
delayed.
We  investigated  how  isoﬂurane  affects  the  evoked  poten-
tials  of  hypoxic  hippocampal  slice.  In  hypoxic  groups,  the
average  decay  time  of  OPS  was  about  144  s,  the  recov-
ery  ratio  of  OPS  and  amplitude  of  OPS  were  both  small
after  restoration  of  oxygen  and  glucose  supply  (Fig.  1A).
It  indicated  the  hypoxic  damage  of  synaptic  transmission
between  hippocampal  neurons.  The  exposure  to  isoﬂurane
caused  dose-dependent  increase  in  recovery  ratio  of  OPS
and  amplitude  of  OPS.  It  suggests  that  isoﬂurane  treatment
increased  the  hypoxic  tolerance  of  the  hippocampal  slice.
The  delay  of  HIP  onset,  the  extension  of  HIP  duration  and
decreased  incidence  of  HIP  in  different  dosage  of  isoﬂu-
rane  also  demonstrated  that  isoﬂurane  exposure  postpones
the  occurrence  of  irreversible  hypoxic  damage  and  increases
duration  of  reversible  damage.  Collectively,  it  suggests  that
r
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soﬂurane  treatment  reduces  the  hypoxic  damage  of  neurons
nd  protects  the  synaptic  functions  from  hypoxic  damage.
The  protective  effect  of  isoﬂurane  may  result  from
nhibition  of  neurotransmitter  amino  acid  like  Glu,  a  major
eurotransmitter  in  the  CA1  region  of  the  hippocampus.
eports  suggest  that  excitatory  amino  acids  (EAA),  including
lu  and  Asp,  play  a  key  role  in  the  hypoxic  brain  damage
echanism.29--31 NMDA  receptor  is  a  major  receptor  of  EAA
nd  its  activation  results  in  intracellular  Ca2+ overload  in
ypoxia.32,33 In  hypoxia  group,  Asp  and  Glu  concentrations
n  perfusion  solution  were  increased  1.32  and  1.27-fold,
espectively  (Table  1).  Isoﬂurane  treatment  reduced  the
ypoxia-induced  release  of  Asp  and  Glu,  thus  reducing
he  excitatory  toxicity.  GABA  is  an  inhibitory  neurotrans-
itter  in  CNS  that  can  protect  neurons  from  hypoxic
amage.34,35 This  study  showed  that  isoﬂurane  treatment
an  increase  the  concentration  of  GABA  in  perfusion  ﬂuid,
hich  may  be  a  neuroprotecting  mechanism  of  isoﬂurane
uring  hypoxia.  Another  anesthetic  propofol  was  reported
o  increases  afﬁnity  between  GABA  and  its  receptor,  thus
ctivating  the  GABA  receptor  directly  to  result  in  enhanced
embrane  current  ﬂow  and  GABA-induced  hypopolarized
nhibition.3 Glycine  (Gly)  is  an  EAA  modulator  that  increases
he  sensitivity  of  NMDA  receptor  to  EAA,  amplifying  the
xcitatory  toxicity  induced  by  EAA.36--38 Gly  was  found
ncreased  in  the  hypoxia  group,  which  may  facilitate  the
xcitatory  toxicity  (Table  1).  Isoﬂurane  treatment  reversed
he  elevation  of  hypoxia-induced  Gly  concentration  in  dose-
ependent  manner,  suggesting  the  CNS  protecting  effects
f  isoﬂurane.  The  data  showed  none  effect  of  isoﬂurane  on
he  release  of  Gln,  which  may  not  directly  associated  with
he  neuroprotective  mechanism  of  isoﬂurane.  Brain  hypoxia
ay  cause  ATP  exhaustion,  inﬂux  of  Na+ and  Cl− efﬂux  of  K+
nd  H2O  resulting  in  cellular  edema.  In  contrast,  excessive
elease  of  Glu  over-excites  the  neurons  and  causes  an
nﬂux  of  Ca2+, and  increase  in  NMDA  dependent  Ca2+ inﬂux.
his  results  in  overload  of  intracellular  Ca2+ that  initiates
nzyme  activation,  protein  hydrolysis,  formation  of  oxygen
ree  radicals,  DNA  damage  and  neuronal  cell  death.  Our
ata  shows  that  isoﬂurane  diminishes  hypoxia-induced
ellular  edema  and  mitochondrial  damage.  Based  on  data,
e  hypothesize  that  the  other  potential  mechanisms  by
hich  isoﬂurane  protects  CNS  from  hypoxic  damage  include
odulation  of  Ca2+,  clearance  of  oxygen  free  radicals,
p-regulation  of  GABA  receptor  and  inhibition  of  NMDA
eceptor.  Furthermore,  we  found  that  isoﬂurane  treatment
aused  inhibition  of  hypoxia  induced  levels  of  mRNA  of
aspase-3  and  PARP.  Apoptosis  can  be  executed  mainly  by
wo  pathways:  caspase-9  dependent  mitochondrial  intrinsic
nd  caspase-8  dependent  extrinsic.  Both  pathways  lead
o  activation  of  executioner  caspase-3  which  ultimately
auses  cell  death  by  cleaving  a  number  of  cytoplasmic  and
uclear  substrates  like  PARP.  This  study  found  that  isoﬂu-
ane  suppressed  the  expression  levels  of  apoptotic  genes
aspase-3  and  PARP  in  dose-dependent  manner  (Fig.  3).
In  conclusion,  isoﬂurane  exposure  provides  neuropro-
ection  against  to  hypoxic  ischemic  brain  injuries  in  rat
rain.  Isoﬂurane  exposure  reduces  the  hypoxic  damage  ofelease  of  Asp  and  Glu  and  enhances  the  release  of  GABA.
hese  amino  acid  neurotransmitter  help  protect  CNS  from
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320  
ypoxic  damage.  The  basic  mechanism  behind  neuropro-
ection  appears  to  be  inhibition  of  apoptosis  induced  by
ypoxia.  This  study  shows  insights  for  using  isoﬂurane  as  a
afe  anesthetic  in  clinical  practices  as  well  as  in  veterinary
ractices.
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